In addition to 1.2‐fold increasing AFP in HBV patients with cirrhosis compare to CHB patients without cirrhosis (P < .05), the level of AFP in HBV‐HCC patients with antiviral therapy was ~60% lower than those in the patients without no‐antiviral (P < .05). Here, AFP is linked to hepatocellular carcinoma.